Last reviewed · How we verify
GSK Biologicals Influenza Vaccine GSK576389A
GSK Biologicals Influenza Vaccine GSK576389A is a Influenza vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Seasonal influenza prevention in adults.
This vaccine stimulates the immune system to recognize and respond to influenza virus antigens, providing protection against seasonal influenza infection.
This vaccine stimulates the immune system to recognize and respond to influenza virus antigens, providing protection against seasonal influenza infection. Used for Seasonal influenza prevention in adults.
At a glance
| Generic name | GSK Biologicals Influenza Vaccine GSK576389A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
GSK576389A is an investigational influenza vaccine designed to elicit both humoral and cellular immune responses against influenza virus strains. By presenting viral antigens to the immune system, the vaccine trains B cells and T cells to recognize and neutralize the virus upon natural exposure, reducing infection risk and disease severity.
Approved indications
- Seasonal influenza prevention in adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over (PHASE2)
- Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations (PHASE2)
- Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A (PHASE2)
- Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults (PHASE2)
- Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults (PHASE2)
- Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK Biologicals Influenza Vaccine GSK576389A CI brief — competitive landscape report
- GSK Biologicals Influenza Vaccine GSK576389A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK Biologicals Influenza Vaccine GSK576389A
What is GSK Biologicals Influenza Vaccine GSK576389A?
How does GSK Biologicals Influenza Vaccine GSK576389A work?
What is GSK Biologicals Influenza Vaccine GSK576389A used for?
Who makes GSK Biologicals Influenza Vaccine GSK576389A?
What drug class is GSK Biologicals Influenza Vaccine GSK576389A in?
What development phase is GSK Biologicals Influenza Vaccine GSK576389A in?
What are the side effects of GSK Biologicals Influenza Vaccine GSK576389A?
Related
- Drug class: All Influenza vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Seasonal influenza prevention in adults
- Compare: GSK Biologicals Influenza Vaccine GSK576389A vs similar drugs
- Pricing: GSK Biologicals Influenza Vaccine GSK576389A cost, discount & access